Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial
Keros Therapeutics, Inc. (NASDAQ:KROS) has announced it will discontinue all development of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) after topline data from the TROPOS Phase 2 trial revealed significant safety concerns.
The trial was halted early following a dose-dependent increase in pericardial effusions, a serious cardiac side effect, particularly at higher doses of 3.0 mg/kg and 4.5 mg/kg. In January 2025, all dosing, including lower-dose and placebo arms, was stopped as new adverse events emerged during ongoing safety reviews. The incidence and severity of pericardial effusions in the cibotercept arms exceeded those seen in placebo and were notably higher than rates reported in comparable studies of MRK's Winrevair (sotatercept).
A picture of a pharma technician preparing an IV injection of a biopharmaceutical product.
Efficacy outcomes were also disappointing, with no clinically meaningful improvements observed in pulmonary vascular resistance or six-minute walk distance. No major safety signals for other adverse events, such as hemoglobin changes or bleeding, were detected. Due to the early termination, interpretation of the 24-week data is limited.
In response, Keros Therapeutics, Inc. (NASDAQ:KROS) will reduce its workforce by about 45%, leaving 85 full-time employees and aiming for $17 million in annualized cost savings.
Keros Therapeutics, Inc. (NASDAQ:KROS) will now explore strategic alternatives and reassess cibotercept's potential in other indications.
While we acknowledge the potential of KROS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KROS and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
29 minutes ago
- Business Insider
RBC Capital Sticks to Its Hold Rating for CME Group (CME)
RBC Capital analyst Ashish Sabadra maintained a Hold rating on CME Group (CME – Research Report) on June 8 and set a price target of $269.00. The company's shares closed yesterday at $268.35. Confident Investing Starts Here: Sabadra covers the Industrials sector, focusing on stocks such as APi Group, Cintas, and Equifax. According to TipRanks, Sabadra has an average return of 6.1% and a 62.50% success rate on recommended stocks. In addition to RBC Capital, CME Group also received a Hold from KBW's Kyle Voigt in a report issued on June 4. However, on the same day, Oppenheimer reiterated a Buy rating on CME Group (NASDAQ: CME). CME market cap is currently $98.82B and has a P/E ratio of 27.57. Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CME in relation to earlier this year. Last month, Daniel Kaye, a Director at CME sold 500.00 shares for a total of $141,205.00.
Business Insider
29 minutes ago
- Business Insider
Nasdaq (NDAQ) Gets a Buy from RBC Capital
RBC Capital analyst Ashish Sabadra maintained a Buy rating on Nasdaq (NDAQ – Research Report) on June 8 and set a price target of $95.00. The company's shares closed yesterday at $85.65. Confident Investing Starts Here: According to TipRanks, Sabadra is a 5-star analyst with an average return of 6.1% and a 62.50% success rate. Sabadra covers the Industrials sector, focusing on stocks such as APi Group, Cintas, and Equifax. Currently, the analyst consensus on Nasdaq is a Moderate Buy with an average price target of $84.58. NDAQ market cap is currently $49.15B and has a P/E ratio of 38.82. Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NDAQ in relation to earlier this year. Last month, Pc Nelson Griggs, the Pres. Capital Access Platforms of NDAQ sold 8,000.00 shares for a total of $664,240.00.
Business Insider
an hour ago
- Business Insider
‘Nothing Lasts Forever,' Says Top Investor About Palantir Stock
Palantir (NASDAQ:PLTR) stock presents investors with quite a quandary. Confident Investing Starts Here: On the one hand, there is no denying that the company has delivered incredible growth over the past few years. Its revenues are skyrocketing, its margins are strong, and its list of customers continues to grow by leaps and bounds. Its share price has responded in kind, surging by over 466% over the past twelve months. And therein lies the rub, as PLTR is now trading at elevated multiples that are far and above the sector average. This leads to the question of whether all that company growth has led to enthusiasm that is a bit too optimistic. Top investor Riyado Sofian is decidedly on the fence, and is not sure which way the winds will blow. 'It's hard to decide whether to buy or sell — best to just hold it,' states the 5-star investor, who is in the top 3% of TipRanks' stock pros. Sofian outlines the bull case, describing a company that has introduced game-changing AI technology that sets the firm apart from its peers. Beyond the growing sales, profits, and customers, the investor also points out that revenues from Palantir's top 20 customers increased by 26% year-over-year, a strong indication of customer satisfaction. While the company continues to raise its guidance, it often succeeds in going well beyond these numbers, notes Sofian, and it has repeatedly 'destroyed its guidance' in previous quarters. In other words, more massive growth could be on the horizon for Palantir. 'All things considered, this is execution on an elite level — there's no denying it,' adds Sofian. And yet, judging by traditional metrics, the company is overvalued, the investor acknowledges, and its narrative as 'the most important AI company in the West' is what has powered its continuing ascent. For that reason, as long as the company's growth continues apace, PLTR should continue to rise as well. However, that is far from certain, and at a valuation of 100x its revenues, there is practically no room for error if the impressive rate starts to slow. To this point, Sofian reminds investors that nothing lasts forever. With neither a Buy nor a Sell looking particularly appealing, Sofian is splitting the difference and rating PLTR shares a Hold (i.e. Neutral). (To watch Sofian's track record, click here) That stance is echoed across Wall Street. Of the 18 analyst reviews on file, 11 say Hold, while just 3 recommend Buy and 4 suggest Sell, making PLTR a consensus Hold. The average 12-month price target sits at $101.06, implying a ~23% downside from current levels. (See PLTR stock forecast) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
